載入...
A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles of paclitaxel 175 mg / m2 and carboplatin AUC5 were a...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Russo |
| 出版: |
Remedium Group LLC
2019-06-01
|
| 叢編: | Медицинский совет |
| 主題: | |
| 在線閱讀: | https://www.med-sovet.pro/jour/article/view/3060 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|